AbCellera Appoints Neil Berkley as Chief Business Officer
July 13 2021 - 9:00AM
Business Wire
AbCellera (Nasdaq: ABCL), a technology company with a
centralized operating system for next-generation antibody
discovery, announced today that Neil Berkley has been appointed as
Chief Business Officer (CBO). Mr. Berkley’s role will include
leading the strategy and continued growth of AbCellera’s
partnership business, which currently includes a diverse portfolio
of more than 100 programs with drug developers of all sizes.
“Neil brings a wealth of business development experience that
will be instrumental as we continue to execute our long-term
strategy of using partnerships to accelerate the development of
antibody therapeutics for a wide array of diseases,” said Carl
Hansen, Ph.D., CEO of AbCellera. “We are excited to welcome Neil to
the team and look forward to his leadership in expanding our
commercial reach across the globe.”
Mr. Berkley has more than 20 years of strategic planning and
corporate and business development experience across a wide range
of transactions and therapeutic indications. He joins AbCellera
from Halozyme Therapeutics, where he served as Vice President, Head
of Business Development. Mr. Berkley has held leadership roles at
Axerovision, COI Pharmaceuticals, Acadia Pharmaceuticals, Cadence
Pharmaceuticals, and GSK. He also cofounded Mpex Pharmaceuticals,
which was acquired by Aptalis, and Vaxiion, a clinical stage
bladder cancer company.
“AbCellera has established itself both as a technology leader in
antibody-based drug discovery and a true innovator in the business
of therapeutic development,” said Mr. Berkley. “I am excited to
join AbCellera’s leadership team and look forward to forging
partnerships across the industry that have the potential to
accelerate the delivery of new treatments for people in need.”
Mr. Berkley earned a B.S. in molecular biology from UC San
Diego, an M.S. in cellular and molecular biology, and an MBA from
San Diego State University.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and
analyzes natural immune systems to find antibodies that its
partners can develop into drugs to prevent and treat disease.
AbCellera partners with drug developers of all sizes, from large
pharmaceutical to small biotechnology companies, empowering them to
move quickly, reduce cost, and tackle the toughest problems in drug
development. For more information, visit ww.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s beliefs and
assumptions and on information currently available to management.
All statements contained in this release other than statements of
historical fact are forward-looking statements, including
statements regarding our ability to develop, commercialize and
achieve market acceptance of our current and planned products and
services, our research and development efforts, and other matters
regarding our business strategies, use of capital, results of
operations and financial position, and plans and objectives for
future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210713005284/en/
Inquiries Media: Jessica Yingling, Ph.D.;
media@abcellera.com, +1(236) 521-6774 Business Development: Neil
Berkley; bd@abcellera.com, +1(604) 559-9005 Investor Relations:
Melanie Solomon; ir@abcellera.com, +1(778) 729-9116
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Sep 2023 to Sep 2024